An investigation for investors in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) shares over potential securities laws violations by Amphastar Pharmaceuticals was announced and NASDAQ:AMPH stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/04/2017 -- Amphastar Pharmaceuticals Inc is under investigation over potential securities laws violations. The investigation was announced on behalf of investors in NASDAQ:AMPH shares in connection certain financial statements made by Amphastar Pharmaceuticals Inc.
Investors who purchased shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether certain statements by Amphastar Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On December 27, 2016 Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to its wholly-owned subsidiary, Armstrong Pharmaceuticals, Inc., for its New Drug Application for Primatene Mist (epinephrine inhalation aerosol). Amphastar Pharmaceuticals Inc said that the CRL indicated that Armstrong should make further changes to the label and packaging for Primatene Mist and then conduct another Human Factor validation study to assess consumers' ability to use the product without the guidance of a doctor or pharmacist. Amphastar is evaluating the content of the letter and plans further discussions with the FDA.
Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) declined on December 28, 2016, to as low as $18.13 per share.
On January 3, 2016, NASDAQ:AMPH shares closed at $18.50 per share.